FDA Approves Fountain Medicine’s CDx for Eli Lilly’s Retevmo to Treat Solid Tumor Patients
The genomic profiling test is approved to identify patients with solid tumors with RET gene fusions who may benefit from Retevmo treatment.
Read MorePosted by Andy Lundin | Oct 10, 2023 | Cancer |
The genomic profiling test is approved to identify patients with solid tumors with RET gene fusions who may benefit from Retevmo treatment.
Read MorePosted by Chris Wolski | Sep 4, 2023 | POC Rapid Assays |
Hilab showcased its point-of-care Hemogram device capable of delivering a complete blood count with the assistance of artificial intelligence.
Read MorePosted by Andy Lundin | Jul 24, 2023 | Cancer, Flow Cytometry |
The technique uses two laser sources and detectors to mitigate noise and autofluorescence, and may help detect fluorescent tags.
Read MorePosted by Chris Wolski | May 19, 2023 | Disease States |
The accuracy of polygenic scores (PGSs) varies between individuals across a continuum of genetic ancestry.
Read MorePosted by Chris Wolski | May 19, 2023 | Miscellaneous |
AMP has published a report to establish recommendations for standardizing germline variants detected by next-generation sequencing (NGS).
Read More